Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO)

NCT04747912 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT04747912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04747912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO)
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
March 2, 2021
Completion date
March 1, 2028
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, lymphoblastic leukemia, ph+ acute lymphoblastic leukemia